2023 年第 6 期 第 18 卷

非小细胞肺癌组织中环指蛋白152和四跨膜蛋白12表达情况及临床意义

Expression and clinical significance of ring finger protein 152 and tetraspanin 12 in non-small cell lung cancer

作者：胡珍珍曹念代阅冯娟许建强

英文作者：Hu Zhenzhen Cao Nian Dai Yue Feng Juan Xu Jianqiang

单位：三峡大学第三临床医学院国药葛洲坝中心医院呼吸与危重症医学科，宜昌443002

英文单位：Department of Respiratory and Critical Care Medicine the Third School of Clinical Medicine of Three Gorges University Gezhouba Central Hospital of Sinopharm Yichang 443002 China

关键词：非小细胞肺癌；环指蛋白152；四跨膜蛋白12

英文关键词：Non-smallcelllungcancer;Ringfingerprotein152;Tetraspanin12

• 摘要：

• 目的  研究非小细胞肺癌（NSCLC）组织中环指蛋白152和四跨膜蛋白12的表达情况及临床意义。方法  选取2018年1月至2019年1月国药葛洲坝中心医院收治的NSCLC患者102例为研究对象。比较NSCLC组织及癌旁组织中环指蛋白152和四跨膜蛋白12 mRNA和蛋白的表达水平。统计分析NSCLC组织中环指蛋白152、四跨膜蛋白12蛋白表达与临床和病理特征的关系，分析其对患者预后的影响。单因素及多因素Cox回归方法分析影响NSCLC患者预后的因素。结果  NSCLC组织中环指蛋白152、四跨膜蛋白12 mRNA表达水平及蛋白表达阳性率均明显低于癌旁组织［（1.8±0.8）比（2.6±0.6）、（5.1±1.0）比（6.5±0.5）、45.1%（46/102）比83.3%（85/102）、39.2%（40/102）比88.2%（90/102）］（均P<0.05）。淋巴结转移、肿瘤临床分期Ⅲ期患者NSCLC组织中环指蛋白152、四跨膜蛋白12蛋白表达阳性率明显低于无淋巴结转移、Ⅰ～Ⅱ期患者（均P＜0.05）。环指蛋白152、四跨膜蛋白12阴性表达组患者累积生存率显著低于阳性表达组（均P<0.05）。多因素Cox回归分析结果显示淋巴结转移、肿瘤临床分期Ⅲ期、环指蛋白152阴性、四跨膜蛋白12阴性是NSCLC患者不良预后的独立危险因素，术后辅助化疗是NSCLC患者不良预后的独立保护因素（均P<0.001）。结论  NSCLC组织中环指蛋白152、四跨膜蛋白12表达降低，二者的表达与NSCLC肿瘤临床分期及淋巴结转移有关，是NSCLC预后相关肿瘤标志物。

• Objective    To study the expression and clinical significance of ring finger protein 152(RNF152) and tetraspanin 12 in non-small cell lung cancer(NSCLC). Methods  Totally 102 NSCLC patients admitted to Gezhouba Central Hospital of Sinopharm from January 2018 to January 2019 were selected. The mRNA and protein expression levels of RNF152 and tetraspanin 12 were compared between NSCLC tissues and adjacent tissues. The relationship of the expression of RNF152 and tetraspanin 12 protein in NSCLC tissues with the clinical and pathological characteristics was statistically analyzed, and their impacts on the prognosis of patients were analyzed. Univariate and multivariate Cox regression methods were used to analyze the prognostic factors of NSCLC patients. Results  The expression levels of RNF152 and tetraspanin 12 mRNA and the positive rate of protein expression in NSCLC tissues were significantly lower than those in adjacent tissues［（1.8±0.8） vs （2.6±0.6）, （5.1±1.0） vs （6.5±0.5）, 45.1%（46/102） vs 83.3%（85/102）, 39.2%（40/102） vs 88.2%（90/102）］（all P<0.05）. The positive rates of RNF152 and tetraspanin 12 in NSCLC tissues of patients with lymph node metastasis and tumor clinical stage Ⅲ were significantly lower than those of patients without lymph node metastasis and with stage Ⅰ-Ⅱ (both P<0.05). The cumulative survival rate of patients with negative expression of RNF152 and tetraspanin 12 was significantly lower than that of patients with positive expression(both P<0.05). Multivariate Cox regression analysis showed that lymph node metastasis, tumor clinical stage Ⅲ, negative RNF152 and negative tetraspanin 12 were independent risk factors for poor prognosis of NSCLC patients, and postoperative adjuvant chemotherapy was an independent protective factor for poor prognosis of NSCLC patients(all P<0.001). Conclusions  The expressions of RNF152 and tetraspanin 12 decrease in NSCLC tissues. They are related to the tumor clinical stage and lymph node metastasis of NSCLC, and are tumor markers related to the prognosis of NSCLC.